Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study

Autor: Pizzolato, G., FRANCA CHIERICHETTI, Rossato, A., Cagnin, A., Fabbri, M., Dam, M., Ferlin, G., Battistin, L.
Přispěvatelé: Pizzolato, Gilberto, F., Chierichetti, A., Rossato, A., Cagnin, M., Fabbri, M., Dam, G., Ferlin, L., Battistin
Jazyk: angličtina
Rok vydání: 1995
Předmět:
Adult
Male
drug effects/metabolism
Tomography
Pyrrolidines
Dopamine Agents
pharmacology
Female
Humans
Iodine Radioisotopes
Levodopa
pharmacology
Male
Middle Aged
Parkinson Disease
methods
Antiparkinson Agents
Iodine Radioisotopes
Levodopa
Adult
Aged
Antiparkinson Agent
Receptors
metabolism/radionuclide imaging
Pyrrolidines
Receptor
Dopamine D2
Humans
metabolism/radionuclide imaging
drug effects/metabolism
Dopamine Agent
Tomography
Aged
Tomography
Emission-Computed
Single-Photon
Receptors
Dopamine D2
Parkinson Disease
Middle Aged
Corpus Striatum
pharmacology
Benzamides
Case-Control Studies
Corpus Striatum
Adult
Aged
Antiparkinson Agents
drug effects/metabolism
Dopamine Agents
metabolism/radionuclide imaging
Pyrrolidines
Receptors
Emission-Computed
Single-Photon
Case-Control Studies
Benzamides
Female
pharmacology
drug effects/metabolism
Zdroj: Scopus-Elsevier
Popis: Single photon emission tomography with the ligand [123I]-IBZM was used to image central dopamine D2 receptors in Parkinson's disease patients. The aim was to assess striatal receptor densities in relation to response to L-Dopa therapy. In the parkinsonian patients group who were untreated until SPET study and in the group of patients with a sustained response to chronic L-Dopa, striatal [123I]-IBZM uptake did not differ significantly from mean values of the control group. On the contrary, significantly diminished uptake of [123I]-IBZM was found in the basal ganglia regions of the group of patients who developed a complicated/fluctuating response to chronic L-Dopa treatment. Our results indicate that striatal D2 receptor alterations in Parkinson's disease may contribute to the altered response to L-Dopa.
Databáze: OpenAIRE
Externí odkaz: